Bridging Experience With Eptifibatide After Stent Implantation
Conclusions: Within a limited sample size, bridging with an intravenous GPIIb/IIIa inhibitor appeared feasible. Further study is needed on the optimal strategy to manage patients with recent stenting who need surgical procedures. (Source: Critical Pathways in Cardiology)
Source: Critical Pathways in Cardiology - August 2, 2016 Category: Cardiology Tags: Original Studies Source Type: research
E-067 Endovascular Approach in the Repair of the Middle Cerebral Artery Aneurysm Including Those with Wide Neck and Complex in Morphology-A Case Series
ConclusionsEndovascular repair of the MCA aneurysm inclosing those with wide neck and complex are not only safe and feasible, but associated with high long-term functional outcome. Therefore, endovascular options must be offered to patients prior to surgical clipping of a MCA aneurysm. Further study may be warranted.DisclosuresY. Lodi: None. V. Reddy: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Lodi, Y., Reddy, V. Tags: Electronic poster abstracts Source Type: research
Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program [Original Articles]
Conclusions—
In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications. (Source: Circulation: Cardiovascular Quality and Outcomes)
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes
ConclusionsGPIs achieve similar levels of platelet inhibition at 10 minutes and 1 hour, however abciximab maintains this benefit 24 hours after bolus dose. We did not witness an increased rate of bleeding in patients given new potent P2Y12 inhibitors and a GPI in the modern era.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - June 20, 2016 Category: Cardiology Authors: Lewis E. Holmes, Rohan Gupta, Saissan Rajendran, John Luu, John K. French, Craig P. Juergens Tags: Original Research Article Source Type: research
PM132 Immediate & Short Term Outcome of Using Single Bolus Eptifibatide in Percutaneous Coronary Intervention (Pci) —A Randomized Control Study
Eptifibatide is a molecule isolated from the snake venom. It selectively inhibits the platelet glycoprotein IIb/IIIa receptor. Because of its relatively short half-life, the action is rapid and short.The incidence of non-ST elevated myocardial infarction (NSTEMI) reduced significantly in both urgent & elective PCI. (Source: CVD Prevention and Control)
Source: CVD Prevention and Control - May 31, 2016 Category: Cardiology Authors: S.A. Ahsan, J. Arzu, M.N. Hasan, M. Mahmood, M.A. Siddique, S.M. Zaman, K.S. Hoque Tags: Poster Abstract Source Type: research
PM132 Immediate & Short Term Outcome of Using Single Bolus Eptifibatide in Percutaneous Coronary Intervention (Pci) —A Randomized Control Study
Eptifibatide is a molecule isolated from the snake venom. It selectively inhibits the platelet glycoprotein IIb/IIIa receptor. Because of its relatively short half-life, the action is rapid and short.The incidence of non-ST elevated myocardial infarction (NSTEMI) reduced significantly in both urgent & elective PCI. (Source: CVD Prevention and Control)
Source: CVD Prevention and Control - May 27, 2016 Category: Cardiology Authors: S.A. Ahsan, J. Arzu, M.N. Hasan, M. Mahmood, M.A. Siddique, S.M. Zaman, K.S. Hoque Tags: Poster Abstract Source Type: research
Bolus Plus Infusion Remains Predominant Mode of GP IIB/IIIA Utilization: A 2015 us Hospital Purchasing Study
Platelet glycoprotein IIb/IIIa inhibitors (GPI) are utilized predominantly in patients undergoing percutaneous coronary intervention (PCI); they include the small molecules eptifibatide and tirofiban, and the monoclonal antibody abciximab. Each has bolus and infusion regimens. Clinical trials in product information have 12-24 hour minimum infusion requirements; however, bolus only or shorter infusion regimens have been explored to reduce pharmacy costs. This analysis examines 2015 eptifibatide purchasing to determine the ratio of smaller (bolus) vials to larger (infusion) vials and explore utilization patterns in contempor...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Mitchell, C Smith, R Werner Source Type: research
Distinct Fibrin-{alpha}IIb{beta}3 and Fibrinogen-{alpha}IIb{beta}3 Interactions [Molecular Bases of Disease]
Fibrinogen binding to the integrin αIIbβ3 mediates platelet aggregation and spreading on fibrinogen-coated surfaces. However, in vivo αIIbβ3 activation and fibrinogen conversion to fibrin occur simultaneously, although the relative contributions of fibrinogen versus fibrin to αIIbβ3-mediated platelet functions are unknown. Here, we compared the interaction of αIIbβ3 with fibrin and fibrinogen to explore their differential effects. A microscopic bead coated with fibrinogen or monomeric fibrin produced by treating the immobilized fibrinogen with thrombin was captured by a laser beam and repeatedly brought into contac...
Source: Journal of Biological Chemistry - April 7, 2016 Category: Chemistry Authors: Litvinov, R. I., Farrell, D. H., Weisel, J. W., Bennett, J. S. Tags: Cell Biology Source Type: research
Phase I Experience of Safety of Eptifibatide in Select Patients with Elective Cerebral Aneurysm Embolization (P1.250)
Conclusion: IV Eptifibatide may represent another safe option for rapid and reversible antiplatelet therapy for reduction of thromboembolic complication associated with aneurysmal embolization in select patient population.Disclosure: Dr. Brar has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclose. Dr. Samaan has nothing to disclose. Dr. Song has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Kirmani has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Daniel, J., Brar, J., Moussavi, M., Mehta, S., Korya, D., Chahal, H., Samaan, M., Song, Y.-B., Hussain, M., Kirmani, J. Tags: Aneurysms and Subarachnoid Hemorrhage Source Type: research
Novel Application of Reversible Parental Anti-platelets in Patients with Aneurysmal Subarachnoid Hemorrhage (P1.257)
CONCLUSION: Our results highlight safety of administering IV Eptifibatide to prevent thrombotic complications after endovascular coil embolization in select patients with aneurysmal subarachnoid hemorrhage. Multicenter prospective trials are warranted to corroborate our findingsDisclosure: Dr. Mehta has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Samaan has nothing to disclose. Dr. Daniel has nothing to disclose. Dr. Song has nothing to disclose. Dr. Kirmani has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Samaan, M., Daniel, J., Song, Y.-B., Kirmani, J. Tags: Aneurysms and Subarachnoid Hemorrhage Source Type: research
Eptifibatide Is Safe and May Improve Outcomes in Stroke Patients Undergoing Thrombectomy after Receiving IVtPA (P2.276)
CONCLUSION: The addition of eptifibatide bolus followed by a continuous drip for a mean of 24-hours to IV tPA/thrombectomy was associated with a significantly better 24-hour post-procedure outcome and is safe. This could be due to suppression of inflammation and potential prevention of rethrombosis after treatment. A larger prospective trial is warranted to corroborate our findings.Disclosure: Dr. Mehta has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Kondapalli has nothing to disclose. Dr. Samaan has...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Chahal, H., Mehta, S., Moussavi, M., Korya, D., Brar, J., Kondapalli, S., Samaan, M., Shaikh, A., Kalola, R., Song, Y.-B., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research
Is Eptifibatide a Viable and Safe Option as Stand-Alone Therapy for Acute Ischemic Stroke Patients? (P2.278)
Conclusion: In patients who are not candidates for IV tPA eptifibatide may be a safe and efficacious alternative. None of the patients who were started on eptifibatide had bleeding complications and they had a statistically significant improvement in their level of disability and stroke severity at discharge. To better evaluate the efficacy of eptifibatide, a larger, prospective study should be initiatedDisclosure: Dr. Korya has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclo...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Daniel, J., Samaan, M., Panezai, S., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research
Role of G protein signaling in the formation of the fibrin(ogen)-integrin αIIbβ3-actin cytoskeleton complex in platelets.
Authors: Budnik I, Shenkman B, Savion N
Abstract
Effective platelet function requires formation of a physical link between fibrin(ogen), integrin αIIbβ3, and cytoplasmic actin filaments. We investigated the role of the Gαq, Gαi, and Gα12/13 families of heterotrimeric GTP-binding proteins (G proteins) in the assembly of a ligand-αIIbβ3-actin cytoskeleton complex. Selective and combined activation of the G proteins was achieved by using combinations of various platelet agonists and inhibitors. Formation and stability of fibrinogen-αIIbβ3 interaction were evaluated by the extent of platelet aggregati...
Source: Platelets - April 1, 2016 Category: Hematology Tags: Platelets Source Type: research
Eptifibatide-induced thrombocytopenia leading to acute stent thrombosis
Abstract
A 71-year old female patient with inferior ST-elevation myocardial infarction underwent primary percutaneous coronary intervention (PCI) within 3 h of symptom onset. She was preloaded with 300 mg aspirin and 600 mg clopidogrel before PCI. Coronary angiogram showed occlusion of the right coronary artery. During PCI, eptifibatide was initiated due to the large thrombus burden. Few hours after the procedure, on eptifibatide infusion, a severe drop in platelet count was observed (from 210,000/μl to 35,000/μl) and the infusion was discontinued. One hour later, still under eptifibatide effect an...
Source: Journal of Thrombosis and Thrombolysis - March 23, 2016 Category: Hematology Source Type: research
